Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 2, 2018, Pages 542-544

  Jayol, Aurélie ^a,b   Nordmann, Patrice ^a,c   Poirel, Laurent ^a   Dubois, Véronique ^b,d  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; COLISTIN;

ANTIBIOTIC RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; COLOMBIA; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; FRANCE; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TURKEY (BIRD);

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BETA-LACTAMASE INHIBITORS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; COLISTIN; COLOMBIA; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; FRANCE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; TURKEY;

EID: 85050499866     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx393     Document Type: Letter

References (6)

1. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis 2016; 3: 15-21.
2. Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 2017; 30: 557-96.
3. Monaco M, Giani T, RaffoneMet al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill 2014; 19: pii=20939.
4. Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 2014; 9: 13-25.
5. Wenzler E, Deraedt MF, Harrington AT et al. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-b-lactamaseproducing Gram-negative pathogens. Diagn Microbiol Infect Dis 2017; 88: 352-4.
6. Davido B, Fellous L, Lawrence C et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome b-lactam resistance conferred by metallo-b-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017; 61: e01008-17.